UY37757A - Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante - Google Patents
Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinanteInfo
- Publication number
- UY37757A UY37757A UY0001037757A UY37757A UY37757A UY 37757 A UY37757 A UY 37757A UY 0001037757 A UY0001037757 A UY 0001037757A UY 37757 A UY37757 A UY 37757A UY 37757 A UY37757 A UY 37757A
- Authority
- UY
- Uruguay
- Prior art keywords
- extracellular domain
- kits
- procedures
- compositions
- recombinant human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543788P | 2017-08-10 | 2017-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37757A true UY37757A (es) | 2018-11-30 |
Family
ID=62846219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037757A UY37757A (es) | 2017-08-10 | 2018-06-01 | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11708418B2 (https=) |
| EP (3) | EP3587445B1 (https=) |
| JP (3) | JP6833851B2 (https=) |
| KR (2) | KR102631281B1 (https=) |
| CN (2) | CN117820498A (https=) |
| AR (1) | AR112357A1 (https=) |
| AU (2) | AU2018313028B2 (https=) |
| BR (1) | BR112020002636A2 (https=) |
| CA (1) | CA3070789A1 (https=) |
| EA (1) | EA202090265A1 (https=) |
| ES (2) | ES2911243T3 (https=) |
| HU (1) | HUE065510T2 (https=) |
| MX (3) | MX2020001489A (https=) |
| PL (1) | PL3587445T3 (https=) |
| PT (1) | PT3587445T (https=) |
| TW (1) | TW201910349A (https=) |
| UY (1) | UY37757A (https=) |
| WO (1) | WO2019030581A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE065510T2 (hu) * | 2017-08-10 | 2024-05-28 | Grifols Diagnostic Solutions Inc | Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke |
| US11746140B2 (en) * | 2018-02-20 | 2023-09-05 | F. Hoffman-La Roche Ag | Composition comprising recombinant GPlbα receptor protein |
| CN112048019B (zh) * | 2019-06-06 | 2023-05-09 | 鲁南制药集团股份有限公司 | 抗人cd47单克隆抗体 |
| CN116635420A (zh) * | 2020-09-10 | 2023-08-22 | 英创远达制药公司 | 血液筛查方法 |
| KR20230066404A (ko) | 2020-09-10 | 2023-05-15 | 카시 파마슈티컬스, 인코포레이티드 | 혈액 스크리닝 방법 |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| CN114917413B (zh) * | 2022-06-14 | 2023-04-28 | 健诺维(成都)生物科技有限公司 | 一种负载重组多肽的羊膜及其制备方法 |
| WO2024172419A1 (ko) * | 2023-02-16 | 2024-08-22 | 주식회사 디엔티 | Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물 |
| CN117723749B (zh) * | 2024-02-07 | 2024-06-04 | 南昌大学 | 基于分子粘合剂的动态光散射免疫传感检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6506551B1 (en) * | 1999-10-08 | 2003-01-14 | North Shore - Long Island Jewish Research Institute | CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia |
| AU2001273121A1 (en) * | 2000-06-30 | 2002-01-14 | Pharmacia And Upjohn Company | Recombinant staphylococcus aureus peptide deformylase |
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| AU2005235811B2 (en) * | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| WO2008037257A2 (en) * | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| PL2185589T3 (pl) * | 2007-06-01 | 2016-09-30 | Środki wiążące receptor regionu stałego Fc immunoglobuliny | |
| EP2573112A1 (en) * | 2007-10-11 | 2013-03-27 | The Hospital For Sick Children | Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| EP2370467B1 (en) * | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| WO2010083253A2 (en) * | 2009-01-14 | 2010-07-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| HUE030100T2 (en) * | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
| US20130029358A1 (en) * | 2010-04-01 | 2013-01-31 | Ludwig Institute For Cancer Research Ltd. | Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof |
| AU2011295715B9 (en) * | 2010-09-03 | 2017-02-23 | Abbvie Stemcentrx Llc | Novel modulators and methods of use |
| EP2530089A1 (en) * | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| KR102100388B1 (ko) * | 2012-02-06 | 2020-04-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| US9926373B2 (en) * | 2012-04-27 | 2018-03-27 | Novo Nordisk A/S | Human CD30 ligand antigen binding proteins |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| US9447193B2 (en) * | 2013-03-24 | 2016-09-20 | Development Center For Biotechnology | Methods for suppressing cancer by inhibition of TMCC3 |
| WO2015191546A2 (en) * | 2014-06-10 | 2015-12-17 | The Board Of Regents Of The University Of Texas System | Adp-ribose detection reagents |
| WO2015195531A2 (en) * | 2014-06-18 | 2015-12-23 | Albert Einstein College Of Medicine, Inc. | Syntac polypeptides and uses thereof |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| EP3221358B1 (en) * | 2014-11-18 | 2021-07-21 | Janssen Pharmaceutica, N.V. | Cd47 antibodies, methods, and uses |
| JP6649941B2 (ja) * | 2015-02-16 | 2020-02-19 | 株式会社ファーマフーズ | Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤 |
| US9944679B2 (en) * | 2015-03-16 | 2018-04-17 | The Catholic University Of America | Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag |
| PE20171790A1 (es) * | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
| WO2017043466A1 (ja) * | 2015-09-08 | 2017-03-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ＥｐｈＡ４抗体 |
| AU2016352676A1 (en) * | 2015-11-10 | 2018-05-31 | University Medical Center Hamburg - Eppendorf | ANTIGEN-binding polypeptides directed against CD38 |
| HUE065510T2 (hu) * | 2017-08-10 | 2024-05-28 | Grifols Diagnostic Solutions Inc | Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke |
-
2018
- 2018-06-01 HU HUE19184018A patent/HUE065510T2/hu unknown
- 2018-06-01 EP EP19184018.0A patent/EP3587445B1/en active Active
- 2018-06-01 WO PCT/IB2018/053939 patent/WO2019030581A1/en not_active Ceased
- 2018-06-01 CA CA3070789A patent/CA3070789A1/en active Pending
- 2018-06-01 KR KR1020187017279A patent/KR102631281B1/ko active Active
- 2018-06-01 CN CN202410194213.6A patent/CN117820498A/zh active Pending
- 2018-06-01 CN CN201880000662.5A patent/CN109790210B/zh active Active
- 2018-06-01 ES ES18738376T patent/ES2911243T3/es active Active
- 2018-06-01 EP EP23205907.1A patent/EP4296680A3/en not_active Withdrawn
- 2018-06-01 PT PT191840180T patent/PT3587445T/pt unknown
- 2018-06-01 EP EP18738376.5A patent/EP3464343B1/en active Active
- 2018-06-01 UY UY0001037757A patent/UY37757A/es not_active Application Discontinuation
- 2018-06-01 AU AU2018313028A patent/AU2018313028B2/en active Active
- 2018-06-01 AR ARP180101480 patent/AR112357A1/es unknown
- 2018-06-01 KR KR1020247002508A patent/KR20240015159A/ko active Pending
- 2018-06-01 ES ES19184018T patent/ES2973864T3/es active Active
- 2018-06-01 EA EA202090265A patent/EA202090265A1/ru unknown
- 2018-06-01 TW TW107119019A patent/TW201910349A/zh unknown
- 2018-06-01 JP JP2018530834A patent/JP6833851B2/ja active Active
- 2018-06-01 MX MX2020001489A patent/MX2020001489A/es unknown
- 2018-06-01 PL PL19184018.0T patent/PL3587445T3/pl unknown
- 2018-06-01 BR BR112020002636-0A patent/BR112020002636A2/pt unknown
- 2018-06-01 US US16/079,068 patent/US11708418B2/en active Active
-
2020
- 2020-02-06 MX MX2024005669A patent/MX2024005669A/es unknown
- 2020-02-06 MX MX2024008109A patent/MX2024008109A/es unknown
-
2021
- 2021-02-03 JP JP2021015874A patent/JP7289328B2/ja active Active
-
2023
- 2023-01-31 JP JP2023012758A patent/JP2023041802A/ja active Pending
- 2023-05-19 US US18/320,912 patent/US20240228651A9/en active Pending
- 2023-06-28 AU AU2023204121A patent/AU2023204121B2/en active Active
- 2023-11-20 US US18/514,624 patent/US20240092929A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37757A (es) | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante | |
| ECSP20082648A (es) | Anticuerpos anti-sirpa y métodos de utilización de los mismos | |
| ECSP21010450A (es) | Anticuerpos antisortilina y métodos para su uso | |
| UY37928A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| CO2020000214A2 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
| MX2021007768A (es) | Anticuerpos anti-ctla4 y metodos de uso de los mismos. | |
| CR20230169A (es) | ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485) | |
| CR20180480A (es) | Receptores quiméricos y métodos de uso de los mismos | |
| JOP20170041B1 (ar) | اجسام مضادة ضد vista (b7h5) | |
| JOP20200343A1 (ar) | بروتين ربط مولد ضد مضاد لـ steap1 | |
| CO2019012118A2 (es) | Anticuerpo anti-pd-l1 y uso del mismo | |
| BR112018002844A2 (pt) | receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos | |
| DOP2016000282A (es) | Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1) | |
| MX2020010387A (es) | Metodos para detectar y cuantificar fgf21. | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| EA201991506A1 (ru) | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов | |
| EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы | |
| EA201992317A1 (ru) | Композиции и способы для диагностики рака легких | |
| MX2015009819A (es) | Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo. | |
| MX2020008768A (es) | Agentes anticuerpos anti-cd25. | |
| EA201891196A1 (ru) | Cgrp-антитела и их применение | |
| AR122237A1 (es) | Anticuerpos anti-sortilina y métodos para su uso | |
| AR113757A1 (es) | Anticuerpos anti-cd38 y métodos de uso | |
| Lebedeva et al. | 105-P: APPARENT LOSS OF CD33 MARKER EPITOPE IN A RELAPSED AML PATIENT THAT AFFECTED RESULTS OF LINEAGE SPECIFIC ENGRAFTMENT MONITORING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20241010 |